Method for improving immunogenicity of protein/peptide antigen
AssigneeSinoCellTech Ltd.
InventorsLiangzhi Xie, Yanjing Zhang, Jiandong Zhang
Life of this patent
Estimating the term…
Abstract
Disclosed is a method for improving the immunogenicity of a protein/peptide antigen, the method comprising conjugating a protein/peptide antigen with a sugar to form a sugar-protein/peptide antigen conjugate, which has improved immunogenicity compared to an unconjugated protein/peptide antigen. In particular, the method involves conjugating a pathogen, such as a viral surface protein antigen or a fragment thereof, with a polysaccharide, in particular a capsular polysaccharide of Streptococcus pneumonia. The conjugate with improved immunogenicity can be used to prevent or treat diseases caused by pathogens, in particular diseases caused by coronaviruses.
Claims39
A method for improving the immunogenicity of a protein/peptide antigen, comprising forming a glyco-protein/peptide antigen conjugate by conjugating the protein/peptide antigen with a saccharide,
- wherein the saccharide is capsular polysaccharide of Streptococcus pneumonia,
- wherein the protein/peptide antigen is a virus pathogen-associated protein/peptide antigen selected from human respiratory syncytial virus glycoprotein G (RSV-gpG), hepatitis C virus envelope glycoprotein E1 protein (ECV-E1), hepatitis C virus envelope E2 protein (HCV-E2), influenza B hemagglutinin protein (FLU-B-HA1), influenza A H5N1 hemagglutinin (H5N1-HA), ebola virus glycoprotein (Ebola-GP), ebola virus glycoprotein GP1 (Ebola-GP1), zika virus envelope protein (ZIKV-E), and/or coronavirus spike protein.
A glyco-protein/peptide antigen conjugate with a saccharide increased immunogenicity compared to an unconjugated protein/peptide antigen;
- wherein the saccharide is capsular polysaccharide of Streptococcus pneumonia,
- wherein the protein/peptide antigen is a virus pathogen-associated protein/peptide antigen selected from human respiratory syncytial virus glycoprotein G (RSV-gpG), hepatitis C virus envelope glycoprotein E1 protein (ECV-E1), hepatitis C virus envelope E2 protein (HCV-E2), influenza B hemagglutinin protein (FLU-B-HA1), influenza A H5N1 hemagglutinin (H5N1-HA), ebola virus glycoprotein (Ebola-GP), ebola virus glycoprotein GP1 (Ebola-GP1), zika virus envelope protein (ZIKV-E), and/or coronavirus spike protein.
A method of preventing or treating a disease caused by a pathogen-associated protein/peptide antigen, the method comprising preparing a vaccine or drug comprising the glyco-protein/peptide antigen conjugate of 18 and administering said vaccine or drug to a subject in need thereof.
Dependencies are inferred from the claim text.